Summaries of changes to the WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for children (EMLc) 2017 (2018)

These three summaries have been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. They are intended to communicate changes to the 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. These documents do not replace the full report of the WHO Expert Committee, 2017 and should be read in conjunction with the full report.